- Double-blind, placebo-controlled study aims to measure safety and efficacy of INDV-2000 over 3 months in participants with moderate to severe Opioid Use Disorder.
- INDV-2000 is an investigational non-opioid treatment that acts through the orexin pathway, shown to play a key role in the neurobiology of substance use disorder in animals.
- Recent animal studies have demonstrated that selective Orexin-1 receptor antagonism can reduce self-administration of opioids and synthetic opioids such as fentanyl and remifentanil
Indivior Doses First Subject In Phase 2 Study Of INDV-2000 For Opioid Use Disorder, Assessing Safety And Efficacy Over 3 Months In Treatment-Seeking Individuals
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.